Protara Therapeutics
Develops investigational therapies for cancer, lymphatic malformations, and patients receiving parenteral support.
$3.82
After-hours close+0.01 (+0.26%)
At close$3.81(−4.51%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 82.27%46.24M sharesInsiders 1.95%1.10M sharesOther 15.78%8.86M shares
Shares outstanding 56.20M · Float 49.16M · 87.5% free float
Institutions13F, as of Jun 30, 2026
123 holders · 46.24M shares · 28 new positions · 79 increased · 28 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 4.70M | 8.36% | +4.70Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 3.66M | 6.52% | +268.5K | Aug 7, 2026 |
| Millennium Management LLC | 3.10M | 5.52% | +270.0K | Aug 14, 2026 |
| Velan Capital Investment Management LP | 2.84M | 5.06% | +10.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.30M | 4.09% | +181.1K | Aug 13, 2026 |
| Blackstone Inc. | 2.27M | 4.03% | 0 | Aug 14, 2026 |
| Orbimed Advisors LLC | 2.22M | 3.95% | +2.22Mnew | Aug 14, 2026 |
| Sio Capital Management, LLC | 1.92M | 3.42% | −48.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.60% | 5.21M | 13G | May 15, 2026 ↗ |
| Woodline Partners LP | 7.40% | 1.58M | 13G | Nov 14, 2024 ↗ |
| BlackRock, Inc. | 6.30% | 3.39M | 13G | Apr 27, 2026 ↗ |
| Velan Capital Management LLCincl. Velan Capital Holdings LLC, Velan Horizon Fund LP +5 more | 5.90% | 2.06M | 13G | Dec 17, 2024 ↗ |
| Millennium Management LLC | 5.10% | 2.76M | 13G | Mar 2, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jesse Shefferman | director, officer: CEO and President | 691.8K | 1.23% | Jul 1, 2026 |
| Jacqueline Zummo | officer: Chief R&D Officer | 94.8K | 0.17% | Apr 9, 2026 |
| Leonardo Viana Nicacio | officer: Chief Medical Officer | 78.2K | 0.14% | Jan 21, 2026 |
| William Conkling | officer: Chief Commercial Officer | 76.0K | 0.14% | Jan 21, 2026 |
| Patrick Fabbio | officer: Chief Financial Officer | 64.1K | 0.11% | Jan 27, 2026 |
| Richard S. Levy | director | 51.0K | 0.09% | May 16, 2025 |
| Hannah Fry | officer: VP, Controller | 42.7K | 0.08% | Jan 27, 2026 |
8 ten-percent owners hold 768.0K shares by Form 4, outside the officers-and-directors figure above · 20 people have not refiled in the last 18 months (535.8K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 29, 2026 | Jesse Sheffermandirector, officer: CEO and President | Sale | 215,687 | $4.09 | 721,832 |
| Apr 8, 2026 | Jacqueline Zummoofficer: Chief R&D Officer | Sale | 1,134 | $5.40 | 94,827 |
| Apr 1, 2026 | Jacqueline Zummoofficer: Chief R&D Officer | Sale | 22,598 | $5.26 | 95,961 |
CongressHouse and Senate disclosures
Not reported.